Search results
Results from the WOW.Com Content Network
GLP1 poly-agonist peptides [1] are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor.These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease.
Aleniglipron (development code GSBR-1290) is a small-molecule GLP-1 agonist developed by Structure Therapeutics. [1] It is delivered orally and is in a Phase II trial as of 2023.
VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. It is injectable and is being developed by Viking Therapeutics. [1] [2] [3]
Both competitors have promising lead programs, and enough cash, too.
The GLP-1 agonist would join a crowded market led by Novo Nordisk and the teaming of. Sanofi announced this week that the Food and Drug Administration began to review the company's once-daily type ...
Big pharma has been chasing the GLP-1 craze, with Novo Nordisk and Eli Lilly in the lead. One investor says a smaller player could have the "holy grail" for obesity. Why Viking Therapeutics could ...
GLP-1 agonists' weight reduction effects come from a combination of peripheral effects as well as activity in the brain via the central nervous system. [17] In the brain, GLP-1 agonists reduce weight by crossing the blood-brain barrier in the brain and directly activating the satiety hormones in the ventromedial hypothalamus (Hariyanto, 2021).
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases. Naturally occurring peptides may serve as hormones , growth factors , neurotransmitters , ion channel ligands , and anti-infectives ; peptide therapeutics mimic such functions.